PolyPid (PYPD) News Today $3.43 -0.06 (-1.72%) Closing price 04:00 PM EasternExtended Trading$3.37 -0.06 (-1.78%) As of 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Why Is PolyPid Down Today?Toggle Visibility of Why Is PolyPid Down Today?PolyPid Ltd. (NASDAQ: PYPD) is trading higher today after a wave of positive clinical data and analyst upgrades, though mixed Q2 results and rising expenses provide some headwinds. Positive Sentiment: Roth Capital raised its price target to $10 from $9PolyPid price target raised to $10 from $9 at Roth Capital Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and set a $13.00 target, implying a 279% upside from current levelsBenzinga Positive Sentiment: Phase 3 SHIELD II trial met its primary efficacy endpoint with a 58% reduction in surgical site infectionsPolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results Positive Sentiment: PolyPid reported strong Phase 3 results and appointed Nir Dror as Interim Chairman to bolster leadershipPolyPid Reports Positive Phase 3 Results and Strengthens Leadership Positive Sentiment: Management sees a cash runway extending well into 2026PolyPid sees cash runway ‘well into’ 2026 Positive Sentiment: Short interest fell 61% in July, reducing days-to-cover to just 0.1 Neutral Sentiment: Mid-2025 financial update released showing revenue trends for the first halfPolyPid Releases Mid-2025 Financial Update Neutral Sentiment: Full Q2 2025 earnings call transcript availablePolyPid Ltd. (NASDAQ:PYPD) Q2 2025 Earnings Call Transcript Neutral Sentiment: Q2 highlights noted strategic advances but flagged rising operating expensesPolyPid Ltd (PYPD) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Rising Expenses Neutral Sentiment: Corporate update and Q2 financial results published via GlobeNewswirePolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results Neutral Sentiment: Seeking Alpha also published the full Q2 call transcriptPolyPid Ltd. (PYPD) Q2 2025 Earnings Call Transcript Negative Sentiment: Q2 EPS of ($0.78) missed consensus by $0.25View Press Release Negative Sentiment: Rising operating expenses were highlighted as a drag on marginsPolyPid Ltd (PYPD) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Rising Expenses Posted 2h agoAI Generated. May Contain Errors. PYPD Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period PolyPid price target raised to $10 from $9 at Roth Capital3 hours ago | msn.comPolyPid Releases Mid-2025 Financial Update3 hours ago | theglobeandmail.comPolyPid Reports Strong Phase 3 Results and Financial UpdateAugust 14 at 10:27 AM | msn.comPolyPid Ltd. (NASDAQ:PYPD) Q2 2025 Earnings Call TranscriptAugust 14 at 10:27 AM | msn.comPolyPid Ltd (PYPD) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Rising ExpensesAugust 14 at 10:27 AM | finance.yahoo.comPolyPid Ltd. (PYPD) Q2 2025 Earnings Call TranscriptAugust 13 at 5:04 PM | seekingalpha.comPolyPid sees cash runway ‘well into’ 2026August 13 at 2:01 PM | msn.comPolyPid Reports Positive Phase 3 Results and Strengthens LeadershipAugust 13 at 8:17 AM | tipranks.comPolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial ResultsAugust 13 at 7:30 AM | globenewswire.comPolyPid Ltd.: PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical OfficerAugust 12 at 5:57 PM | finanznachrichten.dePolyPid appoints Tweezer-Zaks as Chief Medical OfficerAugust 12 at 5:57 PM | msn.comPolyPid Appoints New Chief Medical Officer Amid Strategic AdvancementsAugust 12 at 5:57 PM | msn.comPolyPid Ltd. Appoints Dr. Nurit Tweezer-Zaks as Chief Medical OfficerAugust 12 at 9:00 AM | quiverquant.comQPolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical OfficerAugust 12 at 8:00 AM | globenewswire.comPolyPid Ltd. (NASDAQ:PYPD) Given Average Rating of "Buy" by BrokeragesAugust 6, 2025 | americanbankingnews.comPolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025July 30, 2025 | globenewswire.comPYPD: Positive Topline Data From D-PLEX₁₀₀ Trial Contributes to Multiple Subsequent BenefitsJuly 16, 2025 | finance.yahoo.comPolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss MarketJuly 15, 2025 | finance.yahoo.comPolyPid Launches Long-Acting GLP-1 Delivery Platform for Diabetes MarketJuly 15, 2025 | tipranks.comPolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss MarketJuly 15, 2025 | globenewswire.comPolyPid Ltd. (PYPD) Latest Stock News & Headlines - Yahoo FinanceJune 26, 2025 | finance.yahoo.comPolyPid Secures $26.7 Million in Additional Funding to Extend Runway Ahead of D-PLEX₁₀₀ FDA ApprovalJune 18, 2025 | nasdaq.comPolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial ResultsJune 16, 2025 | globenewswire.comPESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection PreventionJune 11, 2025 | globenewswire.comPESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection PreventionJune 11, 2025 | globenewswire.comPolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met ...June 11, 2025 | seekingalpha.comCraig-Hallum Reaffirms Their Buy Rating on PolyPid (PYPD)June 11, 2025 | theglobeandmail.comNano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 TrialJune 11, 2025 | finance.yahoo.comPolyPid price target raised to $13 from $11 at H.C. WainwrightJune 11, 2025 | msn.comPolyPid shares surge on successful D-PLEX100 trial resultsJune 9, 2025 | in.investing.comBriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call TranscriptJune 9, 2025 | globenewswire.comPolyPid’s D-PLEX100 Achieves Positive Phase 3 Results in SHIELD II TrialJune 9, 2025 | tipranks.comPolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary EndpointsJune 9, 2025 | globenewswire.comPolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025June 8, 2025 | finance.yahoo.comPolyPid to Host Conference Call and Webcast to Discuss D-PLEXâ‚₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025June 6, 2025 | globenewswire.comRoth Capital Initiates Coverage of PolyPid (PYPD) with Buy RecommendationJune 6, 2025 | msn.comPolyPid at Lytham Partners: Strategic Advances and Financial StabilityMay 30, 2025 | investing.comPESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data ReadoutMay 30, 2025 | globenewswire.comPolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025May 20, 2025 | globenewswire.comPolyPid Ltd (PYPD) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial ChallengesMay 16, 2025 | finance.yahoo.comPolyPid Ltd. (NASDAQ:PYPD) Q1 2025 Earnings Call TranscriptMay 16, 2025 | msn.comPolyPid Ltd. (PYPD) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comPolyPid Completes Enrollment in Phase 3 Trial of D-PLEX100May 14, 2025 | tipranks.comPolyPid Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 14, 2025 | globenewswire.comA Look Ahead: PolyPid's Earnings ForecastMay 13, 2025 | benzinga.comPolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025April 29, 2025 | globenewswire.comPolyPid to Participate in The Citizens Life Sciences ConferenceApril 22, 2025 | globenewswire.comPolyPid management to meet with OppenheimerApril 17, 2025 | markets.businessinsider.comBarclays Reaffirms Their Hold Rating on PolyPid (PYPD)March 24, 2025 | markets.businessinsider.comPolyPid completes enrollment in SHIELD II Phase 3 trial for D-PLEX100March 12, 2025 | markets.businessinsider.com Get PolyPid News Delivered to You Automatically Sign up to receive the latest news and ratings for PYPD and its competitors with MarketBeat's FREE daily newsletter. Email Address PYPD Media Mentions By Week PYPD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PYPD News Sentiment▼0.390.61▲Average Medical News Sentiment PYPD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PYPD Articles This Week▼162▲PYPD Articles Average Week Get PolyPid News Delivered to You Automatically Sign up to receive the latest news and ratings for PYPD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CVRx News Inogen News Monogram Orthopaedics News KORU Medical Systems News Shoulder Innovations News InfuSystem News Profound Medical News Electromed News LENSAR News Biosig Technologies News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PYPD) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PolyPid Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PolyPid With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access